Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
oroxine 175 mikrogram tabletter
aspen pharma trading ltd. - levothyroxinnatrium - tabletter - 175 mikrogram
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
oroxine 200 mikrogram tabletter
aspen pharma trading ltd. - levothyroxinnatrium - tabletter - 200 mikrogram
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
oroxine 25 mikrogram tabletter
aspen pharma trading ltd. - levothyroxinnatrium - tabletter - 25 mikrogram
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
oroxine 50 mikrogram tabletter
aspen pharma trading ltd. - levothyroxinnatrium - tabletter - 50 mikrogram
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
oroxine 75 mikrogram tabletter
aspen pharma trading ltd. - levothyroxinnatrium - tabletter - 75 mikrogram
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
metformin "accord" 1000 mg filmovertrukne tabletter
accord healthcare b.v. - metforminhydrochlorid - filmovertrukne tabletter - 1000 mg
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
metformin "accord" 850 mg filmovertrukne tabletter
accord healthcare b.v. - metforminhydrochlorid - filmovertrukne tabletter - 850 mg
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
metformin "laurus" 500 mg filmovertrukne tabletter
laurus generics gmbh - metforminhydrochlorid - filmovertrukne tabletter - 500 mg
Den Europæiske Union -
dansk -
EMA (European Medicines Agency)
lytgobi
taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - antineoplastiske midler - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.